Capricor Therapeutics logo

Capricor Therapeutics (CAPR) Q1 2026 Earnings

CAPR·Reported May 12, 2026·After market close

Diluted EPS came in at $-0.59 (-11.3% YoY), missed the $-0.55 consensus by $0.04.

Diluted EPS
$-0.59missed by $0.04
Consensus: $-0.55
SEC

SEC Filings

Financial Snapshot

Trailing eight quarters through Q1 2026

Q1 2026 Earnings FAQ

Common questions about Capricor Therapeutics's Q1 2026 earnings report.

Capricor Therapeutics (CAPR) reported Q1 2026 earnings on May 12, 2026 after market close.

Capricor Therapeutics reported diluted EPS of $-0.59 for Q1 2026.

EPS missed the consensus estimate of $-0.55 by $0.04.

Compared to the same quarter a year prior, diluted EPS declined 11.3% from $-0.53.

You can read the 8-K earnings release (0001104659-26-059380) and the 10-Q periodic report (0001104659-26-060382) directly on SEC EDGAR. The filing index links above go to sec.gov.